Article
Pharmacology & Pharmacy
Yamin Shu, Yufeng Ding, Xucheng He, Yanxin Liu, Pan Wu, Qilin Zhang
Summary: This study evaluated the cost-effectiveness of osimertinib in China and found that, at the current market price, first-line osimertinib therapy may not be cost-effective for patients with EGFR-mutated advanced NSCLC. However, a significantly more favorable cost-effectiveness could be achieved if the price of osimertinib was reduced by 5%.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Oncology
Yvette N. Lamb
Summary: Osimertinib is an effective treatment for non-small cell lung cancer, prolonging survival and showing good tolerability in patients.
Article
Oncology
Ying Cheng, Yong He, Wei Li, He-long Zhang, Qing Zhou, Buhai Wang, Chunling Liu, Andrew Walding, Matilde Saggese, Xiangning Huang, Minhao Fan, Jia Wang, Suresh S. Ramalingam
Summary: The FLAURA China study evaluated the efficacy of first-line osimertinib in Chinese patients with EGFRm advanced NSCLC, showing significant improvements in PFS and OS compared to comparator EGFR TKIs. Safety data were consistent with the known safety profile of osimertinib.
Article
Medicine, General & Internal
D. Planchard, P. A. Janne, Y. Cheng, J. C. -H. Yang, N. Yanagitani, S-W Kim, S. Sugawara, Y. Yu, Y. Fan, S. L. Geater, K. Laktionov, C. K. Lee, N. Valdiviezo, S. Ahmed, J-M Maurel, I Andrasina, J. Goldman, D. Ghiorghiu, Y. Rukazenkov, A. Todd, K. Kobayashi
Summary: The study indicates that first-line treatment with osimertinib-chemotherapy significantly prolongs progression-free survival compared to osimertinib monotherapy in patients with EGFR-mutated advanced NSCLC.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Weiguang Gu, Hua Zhang, Yiyu Lu, Minjing Li, Shuang Yang, Jianmiao Liang, Zhijian Ye, Zhihua Li, Minhong He, Xiaoliang Shi, Fei Wang, Dong You, Weiquan Gu, Weineng Feng
Summary: In this multicenter clinical trial in China, we investigated the efficacy of adding pemetrexed to improve progression-free survival (PFS) in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients. There were no significant differences in PFS between patients with or without concomitant alterations, or between patients receiving EGFR-tyrosine kinase inhibitor (TKI) monotherapy or combined with pemetrexed. However, stratification analysis revealed that TKI monotherapy showed better PFS in non-concomitant group, while TKI combined with pemetrexed showed better PFS in concomitant group. Molecular dynamic analysis supported the better efficacy of TKI combined chemotherapy compared to TKI monotherapy. Additionally, circulating tumor DNA (ctDNA) minimal residual disease (MRD) showed potential as a biomarker for predicting therapeutic efficacy.
CANCER RESEARCH AND TREATMENT
(2023)
Review
Medicine, General & Internal
Yang Lei, Jia Duan, Qiong Zhang, Qing Li
Summary: EGFR-TKI monotherapy is the first-line treatment option for EGFR-mutated NSCLC patients. Combination therapy is widely used, and the efficacy and toxicity of different regimens were evaluated. Osimertinib has the lowest side effects and provides better progression-free survival (PFS) as first-line treatment, while GCP regimen shows the best overall survival (OS) but with limited application due to toxicity.
Article
Oncology
Kentaro Tanaka, Hajime Asahina, Junji Kishimoto, Yoshihiro Miyata, Takahiro Uchida, Kana Watanabe, Kosuke Hamai, Taishi Harada, Yukari Tsubata, Shunichi Sugawara, Kunihiko Kobayashi, Kenji Sugio, Satoshi Oizumi, Isamu Okamoto
Summary: The study investigated the combination of osimertinib with cytotoxic chemotherapy for EGFR-mutated NSCLC patients, finding that adding chemotherapy as a second-line treatment did not prolong survival but was generally well-tolerated.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
K. Tamura, T. Yoshida, K. Masuda, Y. Matsumoto, Y. Shinno, Y. Okuma, Y. Goto, H. Horinouchi, N. Yamamoto, Y. Ohe
Summary: This retrospective study investigated the activity of EGFR-TKIs in untreated EGFR-mutated NSCLC patients with leptomeningeal metastases (LM). The results showed that osimertinib had better outcomes in LM compared to first-generation TKIs, especially in patients with exon 19 deletion.
Article
Oncology
Dong-Wan Kim, Sang-We Kim, D. Ross Camidge, Catherine A. Shu, Kristen A. Marrone, Xiuning Le, Collin M. Blakely, Keunchil Park, Gee-Chen Chang, Sandip Pravin Patel, Gozde Kar, Zachary A. Cooper, Ramin Samadani, Michael Pluta, Rakesh Kumar, Suresh Ramalingam
Summary: This study evaluated the combination of the anti-CD73 antibody oleclumab with the third-generation EGFR TKI osimertinib in previously treated patients with advanced EGFR-mutated NSCLC. The treatment showed moderate activity and acceptable tolerability in this patient population.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Oncology
Ryota Saito, Shunichi Sugawara, Ryo Ko, Koichi Azuma, Ryo Morita, Makoto Maemondo, Satoshi Oizumi, Kazuhisa Takahashi, Hiroshi Kagamu, Yukari Tsubata, Masahiro Seike, Toshiaki Kikuchi, Isamu Okamoto, Morita Satoshi, Hajime Asahina, Kentaro Tanaka, Kenji Sugio, Kunihiko Kobayashi
Summary: This multicenter phase 2 trial assessed the safety and efficacy of osimertinib and platinum-based chemotherapy in previously untreated patients. The results showed that the combination of osimertinib and platinum-based chemotherapy had significant efficacy and acceptable toxicity in EGFR-mutated advanced non-squamous NSCLC patients.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Medicine, General & Internal
Masahiro Tsuboi, Roy S. Herbst, Thomas John, Terufumi Kato, Margarita Majem, Christian Grohe, Jie Wang, Jonathan W. Goldman, Shun Lu, Wu-Chou Su, Filippo de Marinis, Frances A. Shepherd, Ki Hyeong Lee, Nhieu Thi Le, Arunee Dechaphunkul, Dariusz Kowalski, Lynne Poole, Ana Bolanos, Yuri Rukazenkov, Yi-Long Wu
Summary: Among patients with resected, EGFR-mutated, stage IB to IIIA NSCLC, adjuvant osimertinib therapy resulted in significantly longer overall survival compared to placebo in the ADAURA trial. These findings demonstrate that adjuvant osimertinib provides a survival benefit for patients with completely resected, EGFR-mutated, stage IB to IIIA NSCLC.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Yung-Hung Luo, Han Liu, Jason A. Wampfler, Henry D. Tazelaar, Yalun Li, Tobias Peikert, Dan Liu, Konstantinos Leventakos, Yuh-Min Chen, Yanan Yang, Shih-Hwa Chiou, Ping Yang
Summary: This study demonstrates that osimertinib as a second or subsequent line of treatment in patients previously treated with EGFR-TKIs without identification of T790M mutation showed a lower risk of death compared to those who received first-line or second-generation TKIs without subsequent osimertinib. Patients with EGFR mutations and PD-L1 expression >= 50% had a higher risk of treatment failure with osimertinib and worse overall survival. These results suggest that osimertinib as a second-line or subsequent treatment may be a potential alternative for patients without identification of T790M, while high PD-L1 expression is associated with poor outcomes in patients receiving osimertinib.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Juliann Chmielecki, Jhanelle E. Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng-Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, Alexander Todd, Aleksandra Markovets, J. Carl Barrett, Ryan J. Hartmaier, Suresh S. Ramalingam
Summary: By sequencing circulating tumor DNA in patients from the FLAURA trial, this study identifies MET amplification and EGFR C797S mutation as the most frequent acquired resistance mechanisms to first-line osimertinib.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Hirotsugu Kenmotsu, Kazushige Wakuda, Keita Mori, Terufumi Kato, Shunichi Sugawara, Keisuke Kirita, Yasuto Yoneshima, Koichi Azuma, Kazumi Nishino, Shunsuke Teraoka, Takehito Shukuya, Ken Masuda, Hidetoshi Hayashi, Ryo Toyozawa, Satoru Miura, Daichi Fujimoto, Kazuhiko Nakagawa, Nobuyuki Yamamoto, Toshiaki Takahashi
Summary: This study evaluated the efficacy and safety of osimertinib plus bevacizumab in previously untreated patients with advanced nonsquamous NSCLC harboring EGFR-sensitizing mutations. The results showed no significant improvement in progression-free survival with osimertinib plus bevacizumab compared to osimertinib monotherapy. Adverse events were slightly higher in the osimertinib plus bevacizumab group.
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Oncology
Luke S. McLean, Wasek Faisal, Sagun Parakh, Steven C. Kao, Craig R. Lewis, Melvin T. Chin, Mark Voskoboynik, Malinda J. Itchins, Ross R. Jennens, Adam R. Broad, Tessa A. Morris, Benjamin J. Solomon
Summary: This study focused on the outcomes of patients with EGFR-mutated non-small-cell lung cancer who developed leptomeningeal disease and were subsequently treated with osimertinib. The results indicated that osimertinib at a dose of 80 mg daily is an effective therapeutic option for these patients with limited treatment options.
JCO PRECISION ONCOLOGY
(2021)
Article
Oncology
Francesca Trentini, Giulia Mazzaschi, Gianluca Milanese, Claudio Pavone, Denise Madeddu, Letizia Gnetti, Caterina Frati, Bruno Lorusso, Costanza Anna Maria Lagrasta, Roberta Minari, Luca Ampollini, Roberta Eufrasia Ledda, Mario Silva, Nicola Sverzellati, Federico Quaini, Giovanni Roti, Marcello Tiseo
Summary: This study validated a radiomic model capable of dissecting hot and cold tumor immune microenvironment, highlighting the PD-1 to CD8 ratio as the best predictor of clinical outcome among TIME characteristics, and identified RFs that could sharply distinguish between hot and cold TIME categories.
Article
Oncology
Fabiana Perrone, Giulia Mazzaschi, Roberta Minari, Michela Verze, Cinzia Azzoni, Lorena Bottarelli, Rita Nizzoli, Monica Pluchino, Annalisa Altimari, Elisa Gruppioni, Francesca Sperandi, Elisa Andrini, Giorgia Guaitoli, Federica Bertolini, Fausto Barbieri, Stefania Bettelli, Lucia Longo, Maria Pagano, Candida Bonelli, Elena Tagliavini, Davide Nicoli, Alessandro Ubiali, Adriano Zangrandi, Serena Trubini, Manuela Proietto, Letizia Gnetti, Marcello Tiseo
Summary: This study provides insights into the clinical characteristics, treatment response, and survival outcomes of BRAF mutant non-small cell lung cancer, focusing on the differences between V600E and non-V600E populations. The results suggest that V600E mutation may be associated with longer progression-free survival, and factors such as ECOG PS, age, and bone metastasis impact overall survival and progression-free survival.
Article
Oncology
Giulia Mazzaschi, Fabiana Perrone, Roberta Minari, Michela Verze, Cinzia Azzoni, Lorena Bottarelli, Monica Pluchino, Maria Pia Armillotta, Annalisa Ubaldi, Annalisa Altimari, Elisa Gruppioni, Francesca Sperandi, Elisa Andrini, Giorgia Guaitoli, Stefania Bettelli, Lucia Longo, Federica Bertolini, Fausto Barbieri, Maria Pagano, Candida Bonelli, Elena Tagliavini, Davide Nicoli, Alessandro Ubiali, Adriano Zangrandi, Serena Trubini, Manuela Proietto, Letizia Gnetti, Marcello Tiseo
Summary: The study retrospectively evaluated the clinical impact of KRAS mutations in 297 KRAS-mutant NSCLC patients, finding no significant differences in survival and treatment outcomes based on different KRAS mutations, with chemotherapy-treated patients showing worse prognosis and immunotherapy-based regimens potentially prolonging survival. This research may provide valuable insights for predicting outcomes in KRAS-mutant NSCLC patients.
CLINICAL LUNG CANCER
(2022)
Article
Oncology
Giulia Mazzaschi, Alessandro Olivari, Antonio Pavarani, Costanza Anna Maria Lagrasta, Caterina Frati, Denise Madeddu, Bruno Lorusso, Silvia Dallasta, Chiara Tommasi, Antonino Musolino, Marcello Tiseo, Maria Michiara, Federico Quaini, Pellegrino Crafa
Summary: This study aimed to analyze the clinical outcome of GB patients by integrating molecular, immunophenotypic, and MR imaging features. The results showed that MGMT methylation was associated with prolonged overall survival, and GB patients with high mean ADC at MRI had increased survival. PD-L1 and the overall number of TILs and CD163+ TAMs had a marginal impact on patient outcome, while the density of vascular-associated CD4+ lymphocytes emerged as the most significant prognostic factor. Genetic, MR imaging, and immune descriptors were correlated with overall survival. Combining negative predictors (MGMT unmethylation, low mean ADC, and low V-CD4+ TILs) provided a highly significant risk stratification model in GB patients.
Article
Oncology
Fabrizio Tabbo, Lucia Anna Muscarella, Elisa Gobbini, Domenico Trombetta, Stefano Castellana, Angelica Rigutto, Domenico Galetta, Evaristo Maiello, Olga Martelli, Marcello Tiseo, Vieri Scotti, Laura Ghilardi, Vanesa Gregorc, Concetta Sergi, Sara Pilotto, Alessandro Del Conte, Federico Cappuzzo, Diego Cortinovis, Giorgia Osman, Claudia Bareggi, Massimo Di Maio, Antonio Rossi, Giulio Rossi, Emilio Bria, Marco Volante, Giorgio Vittorio Scagliotti, Paolo Graziano, Silvia Novello, Luisella Righi
Summary: This study retrospectively analyzed the clinical data of 290 NSCLC patients who tested positive for ALK by immunohistochemistry and/or fluorescent in situ hybridization. The findings showed that fusion variants did not impact the outcomes of sequential ALK inhibitor treatment. However, V1-positive patients demonstrated prolonged clinical benefits.
EUROPEAN JOURNAL OF CANCER
(2022)
Review
Cell Biology
Rita Balsano, Zita Kruize, Martina Lunardi, Annalisa Comandatore, Mara Barone, Andrea Cavazzoni, Andrea David Re Cecconi, Luca Morelli, Hanneke Wilmink, Marcello Tiseo, Ingrid Garajova, Lia van Zuylen, Elisa Giovannetti, Rosanna Piccirillo
Summary: Cachexia, a metabolic syndrome characterized by severe muscle loss, has a significant impact on quality of life and survival in cancer patients. TGF-beta and other molecules play important roles in the onset and progression of cachexia, and blocking TGF-beta may be a potential mechanism to reverse cachexia.
Article
Oncology
Jordi Remon, Guillermo Villacampa, Francesco Facchinetti, Massimo Di Maio, Florit Marcuse, Marcello Tiseo, Monique Hochstenbag, Lizza E. L. Hendriks, Benjamin Besse
Summary: There is no standard second-line treatment for patients with advanced TET after platinum-based chemotherapy. Although ICB is a potential treatment strategy, its efficacy seems limited with an increased risk of ir-AEs, thus hampering its application in daily clinical practice.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Andrea Camerini, Alessandro Del Conte, Aldo Pezzuto, Vieri Scotti, Francesco Facchinetti, Lucia Pia Ciccone, Marco Perna, Giulia Sartori, Cheti Puccetti, Alberto Ricci, Antonio Santo, Marcello Tiseo, Domenico Amoroso
Summary: The treatment of advanced NSCLC patients unfit for a platinum combination is challenging, and clinical selection criteria, such as older age, comorbidities, and poor performance status, play a crucial role in determining the treatment options. The use of oral metronomic vinorelbine as a single-agent chemotherapy appears to be a frequent choice with acceptable efficacy and safety profiles. However, more research is needed to establish clear guidelines for the selection and outcomes of single-agent chemotherapy in this patient population.
Article
Oncology
Fabiana Perrone, Elda Favari, Giuseppe Maglietta, Michela Verze, Monica Pluchino, Roberta Minari, Roberto Sabato, Giulia Mazzaschi, Annalisa Ronca, Alessandra Rossi, Alessio Cortellini, Federica Pecci, Luca Cantini, Melissa Bersanelli, Federico Quaini, Marcello Tiseo, Sebastiano Buti
Summary: This study aimed to investigate the impact of cholesterol efflux capacity on the clinical outcomes of patients with advanced non-small cell lung cancer and metastatic renal cell carcinoma treated with immune checkpoint inhibitors. The results showed that blood cholesterol levels and serum transporters were associated with patients' overall survival, progression-free survival, and clinical benefit. Passive diffusion demonstrated positive prognostic value in terms of these clinical outcomes.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Oncology
Lecia V. Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, Kenneth O'Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, Sergey Orlov, Chun-Ming Tsai, Michael Boyer, Wu-Chou Su, Jaafar Bennouna, Terufumi Kato, Vera Gorbunova, Ki Hyeong Lee, Riyaz Shah, Dan Massey, Victoria Zazulina, Mehdi Shahidi, Martin Schuler
Summary: The study compared the efficacy of chemotherapy with afatinib in the treatment of EGFR-mutated lung adenocarcinoma. Results showed that afatinib prolonged progression-free survival and improved the quality of life for patients, when compared with chemotherapy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Cesare Gridelli, Marcello Tiseo, Diego Luigi Cortinovis, Maria Rita Migliorino, Vito Barbieri, Paolo Bironzo, Alessandra Bearz, Ilaria Attili, Filippo de Marinis
Summary: ALK tyrosine kinase inhibitors have significantly improved the treatment of NSCLC patients with ALK rearrangements. In Italy, Alectinib and brigatinib are the preferred first-line treatments, with lorlatinib pending approval. Age and performance status have little impact on treatment choice, but treatment compliance and toxicity profile should be considered. The treatment selection should take into account the patient's comorbidities and polypharmacotherapy interactions.
Meeting Abstract
Oncology
D. Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James Chih-Hsin Yang, Ji-Youn Han, Maximilian Hochmair, Ki Hyeong Lee, Angelo Delmonte, Rosario Garcia Campelo, Dong-Wan Kim, Frank Griesinger, Enriqueta Felip, Raffaele Califano, Alexander I. Spira, Michael Thomas, Scott N. Gettinger, Marcello Tiseo, Yuyin Liu, Pingkuan Zhang, Sanjay Popat
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
B. Brown, J. Young, K. Galpin, C. Brown, M. Boyer, V. Chin, P. Hogg, J. Simes
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Pathology
Paolo Bironzo, Laura Melocchi, Valentina Monica, Dario Trebeschi, Fausto Barbieri, Evaristo Maiello, Maria Rita Migliorino, Alessandra Lombardi, Marcello Tiseo, Luisella Righi, Paolo Graziano, Giulio Rossi, Silvia Novello
Summary: This study assesses the agreement of three different ALK IHC clones in 37 FISH-positive NSCLC cases and found that IHC is a reliable tool for the diagnosis of ALK-rearranged NSCLC. TS expression is significantly lower in FISH-positive patients.
Meeting Abstract
Oncology
Sanjay Popat, Hye Ryun Kim, Myung-Ju Ahn, James Yang, Ji-Youn Han, Maximilian Hochmair, Ki Hyeong Lee, Angelo Delmonte, Maria Garcia Campelo, Dong-Wan Kim, Frank Griesinger, Enriqueta Felip, Raffaele Califano, Alexander Spira, Scott Gettinger, Marcello Tiseo, Huamao Lin, Yuyin Liu, Florin Vranceanu, D. Camidge